Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gossamer Bio (GOSS) Short-term Investments (2022 - 2025)

Gossamer Bio (GOSS) has 4 years of Short-term Investments data on record, last reported at $171.3 million in Q3 2025.

  • For Q3 2025, Short-term Investments fell 42.63% year-over-year to $171.3 million; the TTM value through Sep 2025 reached $171.3 million, down 42.63%, while the annual FY2024 figure was $248.4 million, 6.0% down from the prior year.
  • Short-term Investments reached $171.3 million in Q3 2025 per GOSS's latest filing, down from $186.6 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $298.6 million in Q3 2024 and bottomed at $64000.0 in Q1 2022.
  • Average Short-term Investments over 4 years is $194.1 million, with a median of $205.5 million recorded in 2024.
  • Peak YoY movement for Short-term Investments: soared 213359.38% in 2023, then crashed 42.63% in 2025.
  • A 4-year view of Short-term Investments shows it stood at $143.7 million in 2022, then skyrocketed by 83.93% to $264.3 million in 2023, then decreased by 6.0% to $248.4 million in 2024, then crashed by 31.05% to $171.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Short-term Investments were $171.3 million in Q3 2025, $186.6 million in Q2 2025, and $228.9 million in Q1 2025.